Herceptin was the first HER2-targeted therapy for breast cancer. It is a monoclonal antibody that binds to HER2 receptors present on the surface of HER2-positive tumour cells, blocking them from receiving growth signals and flagging them for destruction by the immune system.
Herceptin SC is a subcutaneous formulation that contains hyaluronidase, which temporarily and reversibly degrades hyaluronan, a gel-like substance that forms a barrier between cells under the skin. This enables the subcutaneous formulation of Herceptin to be rapidly dispersed and absorbed over a greater area.
Herceptin is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) and HER2 positive early breast cancer (EBC)
If a patient becomes pregnant while receiving Herceptin, or within 7 months following the last dose of Herceptin, please immediately report pregnancy to the local Roche Adverse Event Line at
M-PK-00001196
This information is intended for HCP only. This is a prescription based drug. Please consult your doctor if you need more information.